Search results for: 'Cancer Diagnostics Market'

06 Mar 2020  |  North America  |  Market Research

Demand Analysis for Handheld Diagnostic Tools in North America, Forecast to 2026

Vehicle Complexity Driving Migration to More Advanced Diagnostics Devices

Infographics

×

Key Issues Addressed

The proliferation of new car features, including advanced driver assistance systems, telematics/infotainment modules, and alternative powertrains, requires automotive repair shops to continually invest in new handheld diagnostic tools that can read the latest vehicle fault codes. Without up-to-date tools, service providers in the automotive afterma...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

The opportunities that come with the utilization of quantum sensing technology in healthcare demonstrate significant potential to revolutionize diagnostics, personalized medicine, and drug development. Quantum sensors offer superior sensitivity and precision, enabling earlier disease detection, easier and non-intrusive monitoring, and producing bet...

06 Jul 2017  |  Asia Pacific  |  Market Research

Growth Opportunities in APAC Oncology Diagnostics Market, Forecast to 2021

Innovation, Technology Integration, and New Customer Segments to Drive New Business Growth

Infographics

×

There is high growth in the Asia-Pacific (APAC) oncology diagnostics market due to increasing incidence of cancer and the drastic reduction in incidence age owing to a plethora of reasons in the regional market. The major drivers for the APAC cancer diagnostics market are increase in adoption of technology platforms, access to targeted cancer thera...

This research service analyzes and provides forecasts of the US hematology diagnostics market from 2012 to 2017. The market is broadly classified into 2 major segments: analyzers and reagents. The US hematology market was sized using a bottom-up revenue model developed from the actual installed base of hematology analyzers in US laboratories, the d...

This study provides an overview of the global point-of-care testing (POCT) industry, which refers to any routine or specialized lab pathology testing conducted rapidly, on-site/near the site of the patient, where care or treatment is provided. COVID-19 radicalization is changing the global diagnostics landscape. Consolidation trends, structural s...

08 Oct 2021  |  North America  |  Market Research

Global Tissue Diagnostics (TDx) Growth Opportunities

Companion Diagnostics (CDx)-specific Advanced Staining and Anatomical Pathology Laboratory Information Systems (APLIS) to Drive Ma

Infographics

×

This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments will g...

31 Mar 2020  |  North America  |  Technology Research

Medical Devices in 2025: An AI Impact Analysis

Transforming Medical Imaging, Patient Monitoring, Ophthalmic and Cancer Diagnostics through Implementation of AI

Infographics

×

Medical device manufacturers are increasingly incorporating artificial intelligence (AI) in their systems with the aim to better assist healthcare providers and also improve care provided to the patients. AI systems have the ability to acquire data, deploy logical rules for processing the data, generate reasonable solutions and automatically recogn...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...